Download PDF
Diabetologie und Stoffwechsel 2019; 14(01): 45-55
DOI: 10.1055/a-0820-1665
Positionspapier
© Georg Thieme Verlag KG Stuttgart · New York

Frühe oder kurzzeitige Insulintherapie bei Typ-2-Diabetes: Stellenwert und Risiko-Nutzen-Bilanz im Rahmen individualisierter Therapiekonzepte

Early or Short-Term Insulin Therapy in Type 2 Diabetes: Significance and Risk/Benefit Balance in the Context of Individualised Therapy Concepts
Markolf Hanefeld
1   Studienzentrum Metabolisch-Vaskuläre Medizin, GWT-TUD GmbH, Dresden, Germany
,
Holger Fleischmann
2   Diabetes & Cardiovascular, Sanofi-Aventis Deutschland GmbH, Berlin, Germany
,
Andreas Liebl
3   Zentrum für Diabetes- und Stoffwechselerkrankungen, Fachklinik Bad Heilbrunn, Germany
,
Thorsten Siegmund
4   Diabetes-, Hormon- und Stoffwechselzentrum, Isar Klinikum München GmbH, München, Germany
› Author Affiliations
Further Information

Publication History

27 September 2018

11 December 2018

Publication Date:
14 February 2019 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Trotz großer Fortschritte in der Qualität der Diabetestherapie wird der Anteil des Diabetes an der Gesamtsterblichkeit in Deutschland mit ca. 20 % angegeben. Diabetesbezogene Komplikationen sind wieder zum Schicksal vieler Patienten (im Besonderen Senioren) mit langer Diabetesdauer geworden. Die Prävention dieser Komplikationen erfordert eine frühe Diagnose sowie eine rasche und konsequente Glykämiekontrolle für den Erhalt und die Remission der residualen B-Zell-Funktion sowie den Schutz des Endothels vor Gluko- und Lipotoxizität. Die glykämische Last gilt für Makro- und Mikroangiopathien im Prinzip gleichermaßen. Mit den bahnbrechenden Ergebnissen der Outcome-Studien mit SGLT2-Inhibitoren und GLP1-Analoga ist sowohl in den Leitlinien als auch in der täglichen klinischen Praxis Bewegung in die Rangfolge der Antidiabetika gekommen. Angesichts dieser sehr positiven Entwicklung muss insofern das Postulat der frühen Insulintherapie im Rahmen einer individualisierten, risikoadjustierten Behandlung überprüft werden. Dieses White Paper demonstriert anhand von gut dokumentierten, kontrollierten Studien, dass bei klinisch kranken Patienten klare Indikationen für eine initiale, intensivierte Insulintherapie bereits zu Beginn des Diabetes gegeben sind. Die Insulintherapie zeigt im Vergleich zu anderen antidiabetischen Behandlungsstrategien den schnellsten Effekt in Bezug auf die Zielerreichung und Glukolipotoxizität. Im Hinblick auf die überwiegende Multimorbidität der Patienten und langanhaltende Remissionen – bis zu 50 % nach 2 Jahren – ist dies außerdem kosteneffektiv. Allerdings sind die Vorteile der frühen Insulintherapie nicht direkt übertragbar auf den langjährigen Diabetes. Jedoch ändert sich da die Situation, wenn nach Ausschöpfung aller Therapieoptionen für orale Antidiabetika und GLP1-Analoga eine weitere Verschlechterung des Diabetes zu beobachten ist oder diabetesbedingte Komplikationen vermehrt auftreten. In diesen Fällen können die positiven Effekte der frühzeitigen Insulinisierung ebenso in Betracht gezogen werden.

Abstract

Despite major advances in the quality of diabetes therapy, the contribution of diabetes to total mortality in Germany is estimated about 20 %. Diabetes-related complications have again become the fate of many (especially elderly) patients with long-term diabetes. Prevention of these complications requires early diagnosis, and a rapid, near to normal glycemic control for the remission and maintenance of residual B-cell function, as well as for the protection of the endothelium from gluco- and lipotoxicity. The glycemic load is in principle equally valid for macroangiopathy and microangiopathy. With the ground-breaking results of the outcome studies with SGLT2 inhibitors and GLP1 analogues, movement has now come into the ranking of antidiabetics in guidelines and daily clinical practice as well. In this eventful, very positive development, the postulate of early insulin therapy must undoubtedly be re-examined as part of an individualised, risk-adjusted treatment. This paper shows with well documented controlled trials that an initial, intensified insulin therapy is indicated already at the onset of diabetes in clinically ill patients. Insulin therapy shows the fastest effect on target attainment and on glucolipotoxicity compared to other antidiabetic treatment strategies. In view of the predominant multimorbidity of patients and long-lasting remissions – up to 50 % after 2 years – this is also cost-effective. Certainly, the benefits of early insulin therapy are not directly transferable to long-term diabetes. However, the situation changes when, once the therapy options with oral therapy and GLP1 analogues have been exhausted, diabetes worsens again or diabetes-related complications occur. In these cases, all the positive effects of early insulinization can be taken into account.

Schlüsselwörter

Typ-2-Diabetes - individualisierte Therapie - frühzeitige Insulintherapie

Key words

type 2 diabetes - individualised therapy - early insulin therapy
 

  • Literatur

  • 1 Jacobs E, Hoyer A, Brinks R. et al. Burden of Mortality Attributable to Diagnosed Diabetes: A Nationwide Analysis Based on Claims Data From 65 Million People in Germany. Diabetes Care 2017; 40: 1703-1709
    CrossrefPubMedGoogle Scholar
  • 2 Rockl S, Brinks R, Baumert J. et al. All-cause mortality in adults with and without type 2 diabetes: findings from the national health monitoring in Germany. BMJ Open Diabetes Res Care 2017; 5: e000451
    PubMedGoogle Scholar
  • 3 Forbes JM, Fotheringham AK. Vascular complications in diabetes: old messages, new thoughts. Diabetologia 2017; 60: 2129-2138
    CrossrefPubMedGoogle Scholar
  • 4 Maffi P, Secchi A. The Burden of Diabetes: Emerging Data. Dev Ophthalmol 2017; 60: 1-5
    PubMedGoogle Scholar
  • 5 Hanefeld M, Meier JJ, Mehnert H. Mikroangiopathien als Diabetikerschicksal – wieder sehr aktuell; Teil 1: Definitionen, Epidemiologie und Pathophysiologie der diabetischen Mikroangiopathie. Diabetes Stoffw Herz 2016; 25: 293-296
    Google Scholar
  • 6 Hanefeld M, Meier JJ, Mehnert H. Mikroangiopathien als Diabetikerschicksal – wieder sehr aktuell; Teil 2: Prävalenz und Inzidenz der diabetischen Mikroangiopathie in Deutschland. Diabetes Stoffw Herz 2016; 26: 349-356
    Google Scholar
  • 7 AWMF. Nationale VersorgungsLeitlinie: Therapie des Typ-2-Diabetes. 2014 www.diabetes.versorgungsleitlinien.de
    PubMedGoogle Scholar
  • 8 Doerr R, Hoffmann U, Otter W. et al. Oral glucose tolerance test and HbA(1)c for diagnosis of diabetes in patients undergoing coronary angiography: [corrected] the Silent Diabetes Study. Diabetologia 2011; 54: 2923-2930
    CrossrefPubMedGoogle Scholar
  • 9 Ceriello A. Hypothesis: the “metabolic memory”, the new challenge of diabetes. Diabetes Res Clin Pract 2009; 86 (Suppl. 01) S2-S6
    CrossrefPubMedGoogle Scholar
  • 10 Del Prato S. Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies. Diabet Med 2009; 26: 1185-1192
    CrossrefPubMedGoogle Scholar
  • 11 Zhang H, Dellsperger KC, Zhang C. The link between metabolic abnormalities and endothelial dysfunction in type 2 diabetes: an update. Basic Res Cardiol 2012; 107: 237
    CrossrefPubMedGoogle Scholar
  • 12 Vasudevan AR, Burns A, Fonseca VA. The effectiveness of intensive glycemic control for the prevention of vascular complications in diabetes mellitus. Treat Endocrinol 2006; 5: 273-286
    CrossrefPubMedGoogle Scholar
  • 13 Ceriello A, Genovese S. Atherogenicity of postprandial hyperglycemia and lipotoxicity. Rev Endocr Metab Disord 2016; 17: 111-116
    CrossrefPubMedGoogle Scholar
  • 14 Lachin JM, Orchard TJ, Nathan DM. et al. Update on cardiovascular outcomes at 30 years of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 2014; 37: 39-43
    CrossrefPubMedGoogle Scholar
  • 15 Lachin JM, Genuth S, Cleary P. et al. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000; 342: 381-389
    CrossrefPubMedGoogle Scholar
  • 16 Weng J, Li Y, Xu W. et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008; 371: 1753-1760
    CrossrefPubMedGoogle Scholar
  • 17 Zinman B, Wanner C, Lachin JM. et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373: 2117-2128
    CrossrefPubMedGoogle Scholar
  • 18 Marso SP, Daniels GH, Brown-Frandsen K. et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375: 311-322
    CrossrefPubMedGoogle Scholar
  • 19 Marso SP, Bain SC, Consoli A. et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016; 375: 1834-1844
    CrossrefPubMedGoogle Scholar
  • 20 American Diabetes Association. 5. Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes-2018. Diabetes Care 2018; 41: S51-S54
    CrossrefPubMedGoogle Scholar
  • 21 Davies MJ, D'Alessio DA, Fradkin J. et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018; 61: 2461-2498
    CrossrefPubMedGoogle Scholar
  • 22 Panduru NM, Nistor I, Groop PH. et al. Considerations on glycaemic control in older and/or frail individuals with diabetes and advanced kidney disease. Nephrol Dial Transplant 2017; 32: 591-597
    CrossrefPubMedGoogle Scholar
  • 23 Garvey WT, Mechanick JI, Brett EM. et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocr Pract 2016; 22 (Suppl. 03) 1-203
    PubMedGoogle Scholar
  • 24 Chamberlain JJ, Rhinehart AS, Shaefer Jr CF. et al. Diagnosis and Management of Diabetes: Synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes. Ann Intern Med 2016; 164: 542-552
    CrossrefPubMedGoogle Scholar
  • 25 Zonszein J, Groop PH. Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the Disease. Diabetes Ther 2016; 7: 621-639
    CrossrefPubMedGoogle Scholar
  • 26 Bianchi C, Daniele G, Dardano A. et al. Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes. Drugs 2017; 77: 247-264
    CrossrefPubMedGoogle Scholar
  • 27 Butler AE, Dhawan S, Hoang J. et al. beta-Cell Deficit in Obese Type 2 Diabetes, a Minor Role of beta-Cell Dedifferentiation and Degranulation. J Clin Endocrinol Metab 2016; 101: 523-532
    CrossrefPubMedGoogle Scholar
  • 28 Reaven GM. HOMA-beta in the UKPDS and ADOPT. Is the natural history of type 2 diabetes characterised by a progressive and inexorable loss of insulin secretory function? Maybe? Maybe not?. Diab Vasc Dis Res 2009; 6: 133-138
    CrossrefPubMedGoogle Scholar
  • 29 Festa A, Williams K, D'Agostino Jr R. et al. The natural course of beta-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study. Diabetes 2006; 55: 1114-1120
    CrossrefPubMedGoogle Scholar
  • 30 Rohrer S, Menge BA, Gruber L. et al. Impaired crosstalk between pulsatile insulin and glucagon secretion in prediabetic individuals. J Clin Endocrinol Metab 2012; 97: E791-E795
    CrossrefPubMedGoogle Scholar
  • 31 White MG, Shaw JA, Taylor R. Type 2 Diabetes: The Pathologic Basis of Reversible beta-Cell Dysfunction. Diabetes Care 2016; 39: 2080-2088
    CrossrefPubMedGoogle Scholar
  • 32 Yan J, Peng D, Jiang F. et al. Impaired pancreatic beta cell compensatory function is the main cause of type 2 diabetes in individuals with high genetic risk: a 9 year prospective cohort study in the Chinese population. Diabetologia 2016; 59: 1458-1462
    CrossrefPubMedGoogle Scholar
  • 33 Sivitz WI. Lipotoxicity and glucotoxicity in type 2 diabetes. Effects on development and progression. Postgrad Med 2001; 109: 55-59, 63–54
    CrossrefPubMedGoogle Scholar
  • 34 Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care 1990; 13: 610-630
    CrossrefPubMedGoogle Scholar
  • 35 Jung KY, Kim KM, Lim S. Therapeutic Approaches for Preserving or Restoring Pancreatic beta-Cell Function and Mass. Diabetes Metab J 2014; 38: 426-436
    CrossrefPubMedGoogle Scholar
  • 36 Scheen AJ. From obesity to diabetes: why, when and who?. Acta Clin Belg 2000; 55: 9-15
    CrossrefPubMedGoogle Scholar
  • 37 Roseman HM. Progression from obesity to type 2 diabetes: lipotoxicity, glucotoxicity, and implications for management. J Manag Care Pharm 2005; 11: S3-S11
    PubMedGoogle Scholar
  • 38 Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773-795
    CrossrefPubMedGoogle Scholar
  • 39 Owens DR. Clinical evidence for the earlier initiation of insulin therapy in type 2 diabetes. Diabetes Technol Ther 2013; 15: 776-785
    CrossrefPubMedGoogle Scholar
  • 40 Lillioja S, Mott DM, Spraul M. et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 1993; 329: 1988-1992
    CrossrefPubMedGoogle Scholar
  • 41 El-Osta A, Brasacchio D, Yao D. et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med 2008; 205: 2409-2417
    CrossrefPubMedGoogle Scholar
  • 42 Ahlqvist E, Storm P, Karajamaki A. et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 2018; 6: 361-369
    CrossrefPubMedGoogle Scholar
  • 43 Zoungas S, Arima H, Gerstein HC. et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol 2017; 5: 431-437
    CrossrefPubMedGoogle Scholar
  • 44 Stratton IM, Adler AI, Neil HA. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412
    CrossrefPubMedGoogle Scholar
  • 45 Gilbert RE, Mann JF. Origin trial investigators,. et al. Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial. Diabetologia 2014; 57: 1325-1331
    CrossrefPubMedGoogle Scholar
  • 46 Kahn SE, Lachin JM, Zinman B. et al. Effects of rosiglitazone, glyburide, and metformin on beta-cell function and insulin sensitivity in ADOPT. Diabetes 2011; 60: 1552-1560
    CrossrefPubMedGoogle Scholar
  • 47 Gerstein HC, Bosch J. Origin Trial Investigators. et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367: 319-328
    CrossrefPubMedGoogle Scholar
  • 48 Meneghini LF. Early insulin treatment in type 2 diabetes: what are the pros?. Diabetes Care 2009; 32 (Suppl. 02) S266-S269
    CrossrefPubMedGoogle Scholar
  • 49 Chiasson JL. Early insulin use in type 2 diabetes: what are the cons?. Diabetes Care 2009; 32 (Suppl. 02) S270-S274
    CrossrefPubMedGoogle Scholar
  • 50 Raz I, Mosenzon O. Early insulinization to prevent diabetes progression. Diabetes Care 2013; 36 (Suppl. 02) S190-S197
    CrossrefPubMedGoogle Scholar
  • 51 Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004; 27: 1028-1032
    CrossrefPubMedGoogle Scholar
  • 52 Li Y, Xu W, Liao Z. et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care 2004; 27: 2597-2602
    CrossrefPubMedGoogle Scholar
  • 53 Ilkova H, Glaser B, Tunckale A. et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 1997; 20: 1353-1356
    CrossrefPubMedGoogle Scholar
  • 54 Park S, Choi SB. Induction of long-term normoglycemia without medication in Korean type 2 diabetes patients after continuous subcutaneous insulin infusion therapy. Diabetes Metab Res Rev 2003; 19: 124-130
    CrossrefPubMedGoogle Scholar
  • 55 Chen HS, Wu TE, Jap TS. et al. Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care 2008; 31: 1927-1932
    CrossrefPubMedGoogle Scholar
  • 56 Wajchenberg BL. beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007; 28: 187-218
    CrossrefPubMedGoogle Scholar
  • 57 Kramer CK, Zinman B, Retnakaran R. Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2013; 1: 28-34
    CrossrefPubMedGoogle Scholar
  • 58 Lingvay I, Kaloyanova PF, Adams-Huet B. et al. Insulin as initial therapy in type 2 diabetes: effective, safe, and well accepted. J Investig Med 2007; 55: 62-68
    CrossrefPubMedGoogle Scholar
  • 59 Harrison LB, Adams-Huet B, Raskin P. et al. beta-cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care 2012; 35: 1406-1412
    CrossrefPubMedGoogle Scholar
  • 60 Mu PW, Chen YM, Lu HY. et al. Effects of a combination of oral anti-diabetes drugs with basal insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes. Diabetes Metab Res Rev 2012; 28: 236-240
    PubMedGoogle Scholar
  • 61 International Diabetes Federation. Global Guideline for Type 2 Diabetes. 2012 https://www.idf.org/e-library/guidelines/79-global-guideline-for-type-2-diabetes
    PubMedGoogle Scholar
  • 62 Alvarsson M, Sundkvist G, Lager I. et al. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 2003; 26: 2231-2237
    CrossrefPubMedGoogle Scholar
  • 63 Hope SV, Knight BA, Shields BM. et al. Random non-fasting C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of hypoglycaemia. Diabetologia 2018; 61: 66-74
    CrossrefPubMedGoogle Scholar
  • 64 Chow LS, Chen H, Miller ME. et al. Biomarkers associated with severe hypoglycaemia and death in ACCORD. Diabet Med 2016; 33: 1076-1083
    CrossrefPubMedGoogle Scholar
  • 65 Pistrosch F, Kohler C, Schaper F. et al. Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes. Acta Diabetol 2013; 50: 587-595
    CrossrefPubMedGoogle Scholar
  • 66 Gerstein HC, Miller ME. Accord Study Group. et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011; 364: 818-828
    CrossrefPubMedGoogle Scholar
  • 67 Duckworth W, Abraira C, Moritz T. et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139
    CrossrefPubMedGoogle Scholar
  • 68 Mellbin LG, Ryden L. Origin Trial Investigators. et al. Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. Eur Heart J 2013; 34: 3137-3144
    CrossrefPubMedGoogle Scholar
  • 69 Laiteerapong N, Ham SA, Gao Y. et al. The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (the Diabetes & Aging Study). Diabetes Care 2018; pii: dc171144
    Google Scholar
  • 70 RISE Consortium. Impact of Insulin and Metformin Versus Metformin Alone on beta-Cell Function in Youth With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. Diabetes Care 2018; 41: 1717-1725
    CrossrefPubMedGoogle Scholar
  • 71 Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary. Endocr Pract 2018; 24: 91-120
    CrossrefPubMedGoogle Scholar
  • 72 American Diabetes Association. 8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2018. Diabetes Care 2018; 41: S73-S85
    CrossrefPubMedGoogle Scholar
  • 73 Lian G, Yue X, Xianxiang Z. et al. Insulinization: A promising strategy for the treatment of type 2 diabetes mellitus. Exp Ther Med 2013; 6: 1300-1306
    CrossrefPubMedGoogle Scholar
  • 74 Hanefeld M, Monnier L, Schnell O. et al. Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular Trials. Diabetes Ther 2016; 7: 187-201
    CrossrefPubMedGoogle Scholar
  • 75 Investigators OT. Characteristics associated with maintenance of mean A1C < 6.5% in people with dysglycemia in the ORIGIN trial. Diabetes Care 2013; 36: 2915-2922
    CrossrefPubMedGoogle Scholar